EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (<i>EGFR</i>) triple mutations with exon 19 deletion (del19), T790M, and cis-C797S (del19/T790M/cis-C797S mutations) frequently occur in patients with non-small cell lung cancer (NSCLC), while progression to frontline <i>EGFR</i>-tyrosine kinase inhibitors (TKIs) and osimertinib was resistant to all clinically available <i>EGFR</i>-TKIs.